SynthesisJournal of gastroenterology and hepatology2026
Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review.
Synthesis in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimGiven the prevalence and chronicity of irritable bowel syndrome (IBS), this systematic review aimed to synthesize evidence on the cost of illness of IBS, with attention to the relative contributions of direct healthcare and indirect non-healthcare costs.
methodsA systematic search of PubMed, Embase, and the Cochrane Library was conducted from inception to August 2025, following PRISMA 2020 guidelines (PROSPERO CRD420251266432). Studies were included if they primarily assessed costs of IBS with sufficiently detailed methodology. Costs were inflation-adjusted to 2024 US dollars using World Bank consumer price indices and prevailing exchange rates. Risk of bias was assessed using the Consensus on Health Economic Criteria (CHEC) list.
resultsThirty-three studies met our inclusion criteria, spanning 14 countries from 1992 to 2022. Mean annual direct healthcare costs per patient ranged widely, from US$193 in Korea to US$31113 in the United States among patients with IBS-C. Among the 10 studies adopting a societal perspective, indirect costs such as absenteeism, presenteeism, and lost productivity frequently constituted a dominant share of total costs. In some settings, non-healthcare costs exceeded direct healthcare costs several-fold (e.g., Sweden: US$17112 vs. US$1943 for IBS-C). Treatment failure and inadequate symptom control were associated with higher expenditures. IBS-C incurred the highest subtype-specific costs, and racial and gender disparities in spending were identified.
conclusionsIBS imposes a considerable global economic burden. When societal perspectives are adopted, indirect costs emerge as a predominant driver of total costs, necessitating holistic management strategies. Importantly, assessments limited to direct healthcare expenditures underestimate the true economic impact of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.